Asia-Pacific region to see significant growth in spine biologics market — 5 observations

Written by Megan Wood | December 06, 2017 | Print  |

The global spine biologics market is anticipated to grow through 2023, according to a Transparency Market Research report.

Here are five observations:


1. The growing popularity of biologics among surgeons and the minimally invasiveness of the procedure will boost the market.


2. The costliness of the biologics process will prove detrimental to market growth.


3. North America leads the space, with Europe coming in second.


4. The Asia-Pacific market will likely significantly grow, owing to an increasing population and improving medical technologies, among other factors.


5. Dominant market players include Alphatec Spine, DePuy Spine, Medtronic, Stryker, Smith & Nephew, Orthovita, Zimmer Biomet, K2M, NuVasive, Lattice Biologics, Arthrex, DMP Spine, Orthofix, RTI Surgical, Wright Medical Technology, Cesca Therapeutics and Precision Spine.


More articles on biologics:
3D-printed PEEK vs. PEKK for spine surgery: 5 takeaways from new study
SeaSpine earns FDA clearance for new OsteoBallast product: 5 things to know
MD Stem Cells reports positive initial results for SCI study: 5 insights


© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months